Standout Papers

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer 2007 2026 2013 2019 2.7k
  1. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer (2008)
    Christos S. Karapetis, Shirin Khambata‐Ford et al. New England Journal of Medicine
  2. Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab (2007)
    Shirin Khambata‐Ford, Christopher R. Garrett et al. Journal of Clinical Oncology
  3. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab (2010)
    Wendy De Roock, Derek J. Jonker et al. JAMA

Immediate Impact

2 by Nobel laureates 16 from Science/Nature 160 standout
Sub-graph 1 of 13

Citing Papers

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
2023 Standout
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
9 intermediate papers

Works of Shirin Khambata‐Ford being referenced

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines
2006
and 3 more

Author Peers

Author Last Decade Papers Cites
Shirin Khambata‐Ford 4391 2191 1521 34 5.4k
Christiane Langer 4496 1956 1493 26 5.7k
Angela Zubel 4746 1921 1346 33 5.6k
Sabine Tejpar 4017 1903 1616 77 5.2k
Michael Schlichting 5076 1988 1551 43 6.0k
Piercarlo Saletti 4167 2040 1565 74 5.4k
Delphine Le Corre 2935 1327 1285 33 4.6k
Rafael G. Amado 4917 2258 1487 56 6.5k
Kelly S. Oliner 4523 2561 1591 67 6.3k
Christopher R. Garrett 2754 2358 758 49 5.2k
Gorana Tomasic 4340 1383 1311 63 5.9k

All Works

Loading papers...

Rankless by CCL
2026